Literature DB >> 6341018

Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrine.

P E Cryer, J E Gerich.   

Abstract

Glucagon normally plays a primary role in promoting glucose recovery from insulin-induced hypoglycemia. Epinephrine compensates largely for deficient glucagon secretion. Glucose recovery from hypoglycemia fails to occur only in the absence of both glucagon and epinephrine. Perhaps as a relatively early feature of autonomic neuropathy, patients with insulin-dependent diabetes mellitus commonly have blunted or absent glucagon secretory responses to hypoglycemia. However, this deficient response is commonly compensated for by epinephrine and glucose recovery occurs. In some patients, progression of adrenergic neuropathy to the point of deficient epinephrine secretory responses to hypoglycemia, coupled with deficient glucagon responses, leads to frequent, severe, and prolonged hypoglycemia. Thus, these glucose counterregulatory systems are of critical importance to patients with insulin-dependent diabetes mellitus. The efficacy of glucose counterregulation in a given patient may determine the degree to which euglycemia can be achieved with aggressive insulin therapy in that patient.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6341018     DOI: 10.2337/diacare.6.1.95

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  22 in total

Review 1.  Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia.

Authors:  Gerald J Taborsky; Thomas O Mundinger
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

2.  System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2009-01

Review 3.  Pathophysiology of sympathoadrenal system.

Authors:  R Giorgino
Journal:  J Endocrinol Invest       Date:  1988-12       Impact factor: 4.256

4.  Role of hepatic autoregulation in defense against hypoglycemia in humans.

Authors:  G Bolli; P De Feo; G Perriello; S De Cosmo; M Ventura; P Campbell; P Brunetti; J E Gerich
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

5.  Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

Review 6.  Advances in β cell replacement and regeneration strategies for treating diabetes.

Authors:  Jacqueline R Benthuysen; Andrea C Carrano; Maike Sander
Journal:  J Clin Invest       Date:  2016-10-03       Impact factor: 14.808

7.  Morphological assessment of pancreatic islet hormone content following aerobic exercise training in rats with poorly controlled Type 1 diabetes mellitus.

Authors:  Matthew W McDonald; Michael R Murray; Katharine E Hall; Earl G Noble; C W James Melling
Journal:  Islets       Date:  2014       Impact factor: 2.694

8.  Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions.

Authors:  G B Bolli; E Tsalikian; M W Haymond; P E Cryer; J E Gerich
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose.

Authors:  Nathan C Geething; Wayne To; Benjamin J Spink; Michael D Scholle; Chia-wei Wang; Yong Yin; Yi Yao; Volker Schellenberger; Jeffrey L Cleland; Willem P C Stemmer; Joshua Silverman
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

Review 10.  Early sympathetic islet neuropathy in autoimmune diabetes: lessons learned and opportunities for investigation.

Authors:  Thomas O Mundinger; Gerald J Taborsky
Journal:  Diabetologia       Date:  2016-06-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.